135729-61-2

135729-61-2 structure

Name: Palonosetron
Chemical Name: palonosetron
CAS Number: 135729-61-2
Molecular Formula: C₁₉H₂₄N₂O
Molecular Weight: 296.407
Catalog: Signaling Pathways GPCR/G Protein 5-HT Receptor
Create Date: 2018-07-25 18:02:37
Modify Date: 2024-01-02 19:03:33
Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).IC50 Value:Target: 5-HT3 ReceptorPalonosetron is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy.

Name	palonosetron
Synonyms	(3aS)-2-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one (S)-(S)-2-(1-Aza-bicyclo[2.2.2]oct-; 3-yl)-2,3,3a,4,5,6-hexahydro-benzo[; de]isoquinolin-1-one (3aS)-2-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one 1H-Benz[de]isoquinolin-1-one, 2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-, (3aS)- Aloxi 2-Qhbiqo (3aS)-2,3,3a,4,5,6-Hexahydro-2-[(3S)-3-quinuclidinyl]-1H-benz[de]isoquinolin-1-one 1H-Benz[de]isoquinolin-1-one, 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-, [S-(R,R)]-, hydrochloride Palonosetron

Description	Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).IC50 Value:Target: 5-HT3 ReceptorPalonosetron is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Research Areas >> Cardiovascular Disease
References	[1]. Celio L, Agustoni F, Testa I, Dotti K, De Braud F.Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.Tumori. 2012 May;98(3):279-86. [2]. Blazer M, Phillips G, Reardon J, Efries D, Smith Y, Weatherby L, Juergens K, Rose J, Griffith N, Bekaii-Saab T.Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either i [3]. Dogan U, Yavas G, Tekinalp M, Yavas C, Ata OY, Ozdemir K.Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.Eur Rev Med Pharmacol Sci. 2012 Apr;16(4):462-8. [4]. Jin Y, Sun W, Gu D, Yang J, Xu Z, Chen J.Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.Eur J Cancer Care (Engl). 2012 Apr 22. [5]. Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglen, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al.2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformati

Density	1.2±0.1 g/cm3
Boiling Point	470.4±45.0 °C at 760 mmHg
Molecular Formula	C₁₉H₂₄N₂O
Molecular Weight	296.407
Flash Point	209.5±21.1 °C
Exact Mass	296.188873
PSA	23.55000
LogP	2.61
Vapour Pressure	0.0±1.2 mmHg at 25°C
Index of Refraction	1.646
Storage condition	-20℃

135729-60-1	135729-61-2
135729-56-5	135729-73-6
813425-83-1	848074-08-8
135729-62-3	135755-51-0
135729-76-9	1330266-39-1
1158522-08-7	940364-43-2
134104-43-1	2153158-30-4
131615-57-1	6906-52-1
1480004-01-0	930439-75-1
1018584-77-4	1375289-11-4